Technologies and Resources for Core Laboratories

核心实验室的技术和资源

• 批准号: 10685612
• 负责人: Laura F. Gibson
• 金额: $ 17.91万
• 依托单位: WEST VIRGINIA UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-15 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10685612
• 关键词: 2019-nCoV; Acute; Address; Air Pollutants; Air Pollution; Appalachian Region; Area; Basic Science; Biological Assay; COVID-19 pandemic; Clinical; Clinical Investigator; Clinical Sciences; Collaborations; Collection; Communities; Containment; Development; Diabetes Mellitus; Diffusion; Disease; Drug Targeting; Education; Elderly; Emerging Communicable Diseases; Equipment; Exposure to; Funding; Future; Future Generations; Gases; Goals; Health; Health Priorities; Health Sciences; Human Resources; Immunology; Individual; Industry; Infrastructure; Inhalation; Inhalation Exposure; Inhalation Toxicology; Institution; Investigation; Investments; Laboratories; Lead; Malignant Neoplasms; Mining; Modeling; Molecular; Molecular Analysis; Molecular Medicine; Morbidity - disease rate; National Institute of General Medical Sciences; Outcome; Outcome Measure; Persons; Positioning Attribute; Pre-Clinical Model; Proteins; Public Health; Research; Research Design; Research Infrastructure; Research Personnel; Research Support; Resources; Rural Community; Rural Health; SARS-CoV-2 infection; Study models; Technology; Time; Toxic effect; Training; Translational Research; Translations; United States Dept. of Health and Human Services; Universities; West Virginia; clinical application; community engagement; design; diagnostic assay; flexibility; health disparity; high throughput screening; hydraulic fracturing; improved; innovation; interest; mortality; novel; occupational health/safety; pathogen; pollutant; population health; programs; toxicant; translational scientist; vaccine development; virology

The Technology and Resources for Core Laboratories Core (Technology Core) of the West Virginia Clinical and Translational Science Institute (WVCTSI) supports research infrastructure critical for rapid translation of innovation to positively impact the health of West Virginians. Importantly, the Technology Core leverages the significant previous IDeA investment in West Virginia, while bringing exciting innovation to support clinical and translational (C/T) investigators’ efforts. Resources described in this Core are essential in providing infrastructure to engage and train C/T scientists with a focus on essential pipeline development as well as diversity of the future generation of C/T investigators. The Technology Core will leverage a strong statewide infrastructure through partnerships with West Virginia University (WVU), Marshall University (MU), NIOSH and the WV DHHR that has been strengthened during the previous funding period. New technical capacity will be provided to investigators and their trainees to support interrogation of current, acute, problems as well as being positioned to take on emerging and future public health crises. The capacity to be nimble in the scope and focus of research that can be supported, both technically and intellectually, is central to the Core. The specific aims that will operationalize our progress towards these goals include to: (1) develop and optimize molecular and protein-based diagnostic assays and support lead compound optimization via an automated pipeline in the newly established Molecular Medicine Laboratory (MML), (2) enable investigations of the health effects of inhalation exposures relevant to rural communities via the state of the art inhalation toxicology facility (iTox) and (3) support translational investigations of pathogens underlying emerging infectious diseases. Focus across the Technology Core is provided by tethering all activities to WVCTSI priority health areas to avoid diffusion of investment and energy, and maximize investment to achieve significant and measurable outcomes. Relevance is obtained by absolute diligence in the design and focus of each aim connecting to a clinical application. In combination, this results in impact on our understanding of specific diseases of interest, and the potential to impact positively on the health of West Virginians while contributing to the broader scientific community.

西弗吉尼亚临床和实验室核心实验室核心（技术核心）的技术和资源 转化科学研究所 (WVCTSI) 支持对快速转化至关重要的研究基础设施 创新对西弗吉尼亚人的健康产生积极影响。重要的是，技术核心利用了 IDeA 之前在西弗吉尼亚州进行了大量投资，同时带来了令人兴奋的创新来支持临床和 本核心中描述的资源对于提供转化（C/T）研究人员的努力至关重要。 吸引和培训 C/T 科学家的基础设施，重点关注重要的管道开发以及 未来一代 C/T 调查员的多样性 技术核心将利用强大的县。 通过与西弗吉尼亚大学 (WVU)、马歇尔大学 (MU)、NIOSH 和 在上一个资助期间加强的 WV DHHR 将加强新的技术能力。 提供给调查人员及其受训人员，以支持对当前的、尖锐的问题以及正在发生的问题的审讯 能够应对新出现的和未来的公共卫生危机 灵活处理范围和重点的能力。 可以在技术和智力上支持的研究是核心具体目标的核心。 这将使我们在实现这些目标方面取得进展，包括：(1) 开发和优化分子和 基于蛋白质的诊断分析，并通过新的自动化管道支持先导化合物优化 建立分子医学实验室 (MML)，(2) 能够研究吸入对健康的影响 通过最先进的吸入毒理学设施 (iTox) 和 (3) 支持与农村社区相关的暴露 对新兴传染病病原体的转化研究。 核心是通过将所有活动束缚在 WVCTSI 优先卫生领域来提供，以避免投资扩散和 能源，并最大限度地投资以实现重大且可衡量的成果。 结合临床应用，每个目标的设计和重点都绝对勤奋。 结果影响我们对感兴趣的特定疾病的理解，并有可能对 西弗吉尼亚州人民的健康，同时为更广泛的科学界做出贡献。